Literature DB >> 32458283

A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study.

Riccardo Calvani1, Anna Picca2, Giovanni Landi1, Federico Marini3, Alessandra Biancolillo3,4, Hélio José Coelho-Junior5,6, Jacopo Gervasoni1,5, Silvia Persichilli1,5, Aniello Primiano5, Annalaura Arcidiacono1, Andrea Urbani1,5, Maurizio Bossola1,5, Anna Rita Bentivoglio1,5, Matteo Cesari7,8, Roberto Bernabei1,5, Maria Rita Lo Monaco9, Emanuele Marzetti1,5.   

Abstract

Dopaminergic nigrostriatal denervation and widespread intracellular α-synuclein accumulation are neuropathologic hallmarks of Parkinson's disease (PD). A constellation of peripheral processes, including metabolic and inflammatory changes, are thought to contribute to neurodegeneration. In the present study, we sought to obtain insight into the multifaceted pathophysiology of PD through the application of a multi-marker discovery approach. Fifty older adults aged 70+, 20 with PD and 30 age-matched controls were enrolled as part of the EXosomes in PArkiNson Disease (EXPAND) study. A panel of 68 circulating mediators of inflammation, neurogenesis and neural plasticity, and amino acid metabolism was assayed. Biomarker selection was accomplished through sequential and orthogonalized covariance selection (SO-CovSel), a multi-platform regression method developed to handle highly correlated variables organized in multi-block datasets. The SO-CovSel model with the best prediction ability using the smallest number of variables was built with seven biomolecules. The model allowed correct classification of 94.2 ± 3.1% participants with PD and 100% controls. The biomarker profile of older adults with PD was defined by higher circulating levels of interleukin (IL) 8, macrophage inflammatory protein (MIP)-1β, phosphoethanolamine, and proline, and by lower concentrations of citrulline, IL9, and MIP-1α. Our innovative approach allowed identifying and evaluating the classification performance of a set of potential biomarkers for PD in older adults. Future studies are warranted to establish whether these biomolecules could serve as biomarkers for PD as well as unveil new targets for interventions.

Entities:  

Keywords:  Aging; Amino acids; Cytokines; Metabolomics; Neurodegeneration; Personalized medicine

Mesh:

Substances:

Year:  2020        PMID: 32458283      PMCID: PMC7525911          DOI: 10.1007/s11357-020-00192-2

Source DB:  PubMed          Journal:  Geroscience        ISSN: 2509-2723            Impact factor:   7.713


  59 in total

1.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

Review 2.  Biomarkers of aging and disease: introduction and definitions.

Authors:  Richard L Sprott
Journal:  Exp Gerontol       Date:  2009-08-03       Impact factor: 4.032

Review 3.  Promise of personalized omics to precision medicine.

Authors:  Rui Chen; Michael Snyder
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2012-11-26

4.  Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

Authors:  Medi Kori; Busra Aydın; Semra Unal; Kazim Yalcin Arga; Dilek Kazan
Journal:  OMICS       Date:  2016-11

Review 5.  Update in therapeutic strategies for Parkinson's disease.

Authors:  Jaime Kulisevsky; Lais Oliveira; Susan H Fox
Journal:  Curr Opin Neurol       Date:  2018-08       Impact factor: 5.710

Review 6.  Th9 cells in the pathogenesis of EAE and multiple sclerosis.

Authors:  Wassim Elyaman; Samia J Khoury
Journal:  Semin Immunopathol       Date:  2016-11-14       Impact factor: 9.623

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

Review 8.  Ageing as a risk factor for neurodegenerative disease.

Authors:  Yujun Hou; Xiuli Dan; Mansi Babbar; Yong Wei; Steen G Hasselbalch; Deborah L Croteau; Vilhelm A Bohr
Journal:  Nat Rev Neurol       Date:  2019-09-09       Impact factor: 42.937

Review 9.  Finding useful biomarkers for Parkinson's disease.

Authors:  Alice S Chen-Plotkin; Roger Albin; Roy Alcalay; Debra Babcock; Vikram Bajaj; Dubois Bowman; Alex Buko; Jesse Cedarbaum; Daniel Chelsky; Mark R Cookson; Ted M Dawson; Richard Dewey; Tatiana Foroud; Mark Frasier; Dwight German; Katrina Gwinn; Xuemei Huang; Catherine Kopil; Thomas Kremer; Shirley Lasch; Ken Marek; Jarrod A Marto; Kalpana Merchant; Brit Mollenhauer; Anna Naito; Judith Potashkin; Alyssa Reimer; Liana S Rosenthal; Rachel Saunders-Pullman; Clemens R Scherzer; Todd Sherer; Andrew Singleton; Margaret Sutherland; Ines Thiele; Marcel van der Brug; Kendall Van Keuren-Jensen; David Vaillancourt; David Walt; Andrew West; Jing Zhang
Journal:  Sci Transl Med       Date:  2018-08-15       Impact factor: 17.956

10.  Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis.

Authors:  Marijan Posavi; Maria Diaz-Ortiz; Benjamine Liu; Christine R Swanson; R Tyler Skrinak; Pilar Hernandez-Con; Defne A Amado; Michelle Fullard; Jacqueline Rick; Andrew Siderowf; Daniel Weintraub; Leo McCluskey; John Q Trojanowski; Richard B Dewey; Xuemei Huang; Alice S Chen-Plotkin
Journal:  PLoS Med       Date:  2019-10-11       Impact factor: 11.069

View more
  8 in total

Review 1.  Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.

Authors:  Xin Li; Xiaoying Fan; Hongtian Yang; Yufeng Liu
Journal:  Mol Neurobiol       Date:  2021-11-26       Impact factor: 5.590

Review 2.  Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.

Authors:  Milan Zimmermann; Kathrin Brockmann
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 3.  Extracellular Vesicles and Damage-Associated Molecular Patterns: A Pandora's Box in Health and Disease.

Authors:  Anna Picca; Flora Guerra; Riccardo Calvani; Hélio José Coelho-Júnior; Francesco Landi; Roberto Bernabei; Roberta Romano; Cecilia Bucci; Emanuele Marzetti
Journal:  Front Immunol       Date:  2020-11-16       Impact factor: 7.561

Review 4.  Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery.

Authors:  Anna Picca; Flora Guerra; Riccardo Calvani; Roberta Romano; Hélio José Coelho-Júnior; Cecilia Bucci; Emanuele Marzetti
Journal:  Biomolecules       Date:  2021-10-13

5.  CCL4 induces inflammatory signalling and barrier disruption in the neurovascular endothelium.

Authors:  Carolina Estevao; Chantelle E Bowers; Ding Luo; Mosharraf Sarker; Alexandra Eva Hoeh; Karen Frudd; Patric Turowski; John Greenwood
Journal:  Brain Behav Immun Health       Date:  2021-10-22

Review 6.  Role of exosomes in the pathogenesis of inflammation in Parkinson's disease.

Authors:  Ke-Lu Li; Hong-Yan Huang; Hui Ren; Xing-Long Yang
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

7.  Genetically Predicted Levels of Circulating Inflammatory Cytokines and the Risk and Age at Onset of Parkinson's Disease: A Two-Sample Mendelian Randomization Study.

Authors:  Yating Zhao; Xiaoqian Zhang; Na Guo; Dandan Tian; Chenguang Zhang; Changqing Mu; Chen Han; Ruixia Zhu; Jian Zhang; Xu Liu
Journal:  Front Aging Neurosci       Date:  2022-03-01       Impact factor: 5.750

8.  Niacin Enhancement for Parkinson's Disease: An Effectiveness Trial.

Authors:  Raymond Chong; Chandramohan Wakade; Marissa Seamon; Banabihari Giri; John Morgan; Sharad Purohit
Journal:  Front Aging Neurosci       Date:  2021-06-17       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.